289 related articles for article (PubMed ID: 30954940)
1.
Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo OO; Tade FI; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Fei B; Schuster DM
J Nucl Med; 2019 Nov; 60(11):1531-1536. PubMed ID: 30954940
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
Fei B; Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo O; Tade F; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Schuster DM
J Urol; 2019 Aug; 202(2):413-421. PubMed ID: 30817240
[TBL] [Abstract][Full Text] [Related]
4. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
6. [
Zanoni L; Bianchi L; Nanni C; Pultrone C; Giunchi F; Bossert I; Matti A; Schiavina R; Fiorentino M; Romagnoli D; Fonti C; Lodi F; D'Errico A; Brunocilla E; Porreca A; Fanti S
Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):390-409. PubMed ID: 34213609
[TBL] [Abstract][Full Text] [Related]
7. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using
Miller MP; Kostakoglu L; Pryma D; Yu JQ; Chau A; Perlman E; Clarke B; Rosen D; Ward P
J Nucl Med; 2017 Oct; 58(10):1596-1602. PubMed ID: 28385791
[No Abstract] [Full Text] [Related]
8. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
9. Effect of hormonal therapy on
Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
[TBL] [Abstract][Full Text] [Related]
12. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on
Abiodun-Ojo OA; Jani AB; Akintayo AA; Akin-Akintayo OO; Odewole OA; Tade FI; Joshi SS; Master VA; Fielder B; Halkar RK; Zhang C; Goyal S; Goodman MM; Schuster DM
J Nucl Med; 2021 Aug; 62(8):1089-1096. PubMed ID: 33517323
[TBL] [Abstract][Full Text] [Related]
13. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
14. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
15. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
16. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
[TBL] [Abstract][Full Text] [Related]
17. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
18. 18F-Fluciclovine Uptake in Celiac Ganglia: A Pitfall in Prostate Cancer PET Imaging.
Wo S; Matesan MC
Clin Nucl Med; 2019 Sep; 44(9):743-745. PubMed ID: 31283598
[TBL] [Abstract][Full Text] [Related]
19. Differential 18F-FDG and 18F-Fluciclovine Uptake Pattern in a Patient With Poorly Differentiated Adenocarcinoma of the Lung and Prostate Cancer Biochemical Recurrence.
Nguyen NC; Muthukrishnan A; Mountz JM
Clin Nucl Med; 2020 Jan; 45(1):e63-e64. PubMed ID: 31652158
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]